New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
07:36 EDTIDRAIdera announces expansion of pipeline into two orphan autoimmune diseases
Idera Pharmaceuticals announced that it plans to initiate clinical development of its lead compound, IMO-8400, for the treatment of patients with polymyositis and patients with dermatomyositis, two orphan autoimmune diseases with high unmet clinical needs. The company plans to submit a protocol to the U.S. Food and Drug Administration in the first half of 2014 for a Phase 1/2 clinical trial to investigate the safety and potential utility of IMO-8400 in these two indications. This represents the execution of a previously announced strategy to expand the clinical development of IMO-8400 in orphan autoimmune disease indications. Based on the results from this study, Idera anticipates that it will pursue separate later-stage clinical trials for each indication.
News For IDRA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 14, 2014
08:19 EDTIDRAIdera Pharmaceuticals advanced IMO-9200 into Phase 1 clinical development
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use